EN | RU
EN | RU

Help Support

Back

Evaluation of the long-term safety and tolerability of a novel mu-opioid agonist in the treatment of patients with chronic lumbodynia or chronic non-cancer pain

Evaluation of the long-term safety and tolerability of a novel mu-opioid agonist in the treatment of patients with chronic lumbodynia or chronic non-cancer pain Evaluation of the long-term safety and tolerability of a novel mu-opioid agonist in the treatment of patients with chronic lumbodynia or chronic non-cancer pain
Evaluation of the long-term safety and tolerability of a novel mu-opioid agonist in the treatment of patients with chronic lumbodynia or chronic non-cancer pain Evaluation of the long-term safety and tolerability of a novel mu-opioid agonist in the treatment of patients with chronic lumbodynia or chronic non-cancer pain

What's new?

Chronic LBP or chronic noncancer pain patients can be recommended NKTR-181, given its favorable safety profile with long-term usage.

According to the results of the SUMMIT-08 LTS study published in the ‘Pain Medicine’ journal, NKTR-181, a novel mu-opioid receptor agonist can be used as a safe and effective therapy for patients suffering from moderate to severe chronic low back pain (CLBP) or other noncancer pain (CNP).

Jeffrey Gudin et al. examined the long-term safety of NKTR-181that may have decreased human abuse potential, in moderate to severe CLBP or other CNP patients. This uncontrolled, multicenter, open-label, long-term study consisted of 3 periods, namely- screening  for about ≤ 21 days, a 52 weeks treatment duration, and safety follow-up (14 days following the last dose of this agonist).

In the opioid-naïve and opioid-experienced patients, NKTR-181 was administered at 100–600 mg dose twice daily (BID). The patients were enrolled from initiation or following conclusion of the phase 3 efficacy study -SUMMIT-07. Adverse event citations, calculations concerning opioid withdrawal, and clinical laboratory tests were all regarded as safety evaluations. The effectiveness was assessed via the reformed Brief Pain Inventory Short Form (BPI-SF).

This study included 638 patients. At each visit, there was a decrease in mean pain intensity from 4.6 ± 2.2 (baseline) to 2.7 ± 1.8 (at the end of the dose titration period). It was found that the intensity of pain decreased after reaching a stable dose of NKTR-181. This was observed in both the opioid and non-opioid groups (see Fig. 1 Abelow). Moreover, similar dynamics were observed in the indicator of the effect of pain (Fig. 1B. After stabilizing the dose of NKTR-181, there was no significant need for OTC drugs for breakthrough pain.


As shown in the table below, the most common treatment-related adverse events (ADEs) were constipation (26%) and nausea (12%).


No mortalities or patients with respiratory depression were witnessed. A constant reduction in mBPI-SF pain intensity and pain interference from baseline to study termination was perceived during the treatment. Only 2% of patients discontinued NKTR-181 due to ineffectiveness, and 11% withdrew from the study because of treatment-related AEs. NKTR-181 dosed at 600 mg BID was normally well-tolerated, with low frequncy of opioid-related adverse events.

Source:

Pain Medicine

Article:

Long-term Safety and Tolerability of NKTR-181 in Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 52-Week Study (SUMMIT-08 LTS)

Authors:

Jeffrey Gudin et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: